# Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

Source: https://onco.cc/trials/nct04912765/  
OnCo record `nct04912765` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of nivolumab in colorectal cancer, run by National Cancer Centre, Singapore, now recruiting.

## Summary

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC is a phase 2, interventional study registered as NCT04912765 by National Cancer Centre, Singapore, with a registry enrolment figure of 60 participants, started 2021-04-15 and due to reach its primary completion in 2026-12. Interventions recorded: Neoantigen Dendritic Cell Vaccine; Nivolumab. Conditions listed: Hepatocellular Carcinoma; Hepatocellular Cancer; Colorectal Cancer; Colorectal Carcinoma; Liver Metastases. Primary outcome: 24-month Relapse Free Survival; Induced immune response against vaccinated NAs. Colorectal eligibility wording from the registry: "* Patients with histologically- or cytologically-diagnosed colorectal cancer with liver-limited metastases are eligible to enrol if:". Sites: Singapore. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT04912765
- Phase: 2
- Setting: An Open Label, Single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) Vaccine and Anti-PD1 (Nivolumab) as Adjuvant Treatment in Resected Hepatocellular Carcinoma (HCC) (Group A) and Liver Metastases From Colorectal Cancer (CRLM) (Group B)
- Sponsor: National Cancer Centre, Singapore
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT04912765: https://clinicaltrials.gov/study/NCT04912765

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04912765.json